Metalyse (Tenecteplase)

Tenecteplase is a recombinant tissue‑type plasminogen activator that binds to fibrin within a thrombus and converts plasminogen to plasmin. The generated plasmin breaks down fibrin strands, leading to clot degradation and reperfusion of the affected vessel.

The dose of Metalyse is individualized by the prescribing clinician based on the patient’s weight, clinical presentation, and local treatment protocols. No fixed dosing information is provided here.

Safety data for tenecteplase in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs the potential risk to the fetus or infant, and decisions should be made by the treating physician.

To request Metalyse, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

The primary alternative thrombolytic is alteplase. Tenecteplase (Metalyse) has a longer half‑life and can be administered as a single bolus, whereas alteplase requires an initial bolus followed by an infusion. Both agents achieve clot lysis, but dosing convenience and pharmacokinetic profiles differ.

Metalyse should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, inspect the vial for particulate matter and ensure the solution remains clear.

Metalyse is given intravenously as a single bolus injection. The administration is performed by a qualified healthcare professional, typically in an acute care setting such as an emergency department or cardiac catheterisation laboratory.

The most serious risks include intracranial hemorrhage, severe systemic bleeding, allergic anaphylactic reactions, and profound hypotension. Immediate medical attention is required if any signs of severe bleeding or hypersensitivity occur.

Metalyse is contraindicated in patients with active internal bleeding, recent intracranial or spinal surgery, known hypersensitivity to tenecteplase or its excipients, and in those who have received another fibrinolytic agent within the preceding 24 hours.